DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

Inclusion Criteria: * Any adult patient age 18-99 years who is planned to undergo vitreo-retinal surgery (pars plana vitrectomy with or without scleral buckle). * If both eyes are involved, both eyes would be eligible for the study. * Willing and able to comply with clinic visits and study related procedures. * Willing and able to sign the informed consent form. Exclusion Criteria: * Patients under age 18. * Patients who are pregnant (must be ruled out in women of child-bearing age with pregnancy test). * Active infectious ocular or systemic disease. * Patients with active infectious ocular or extraocular disease. * Patients actively treated with local or systemic immunosuppression * Use of the following anti-inflammatory or immunomodulating agents (e.g., cyclosporine) systemically, or in the study eye, for the duration of the study (excluding inhalants). Washout periods for medications prior to surgery are as follows: * Systemic corticosteroids - 2 weeks (see exception 5c) * Systemic NSAID over 375 mg per day - 2 weeks * Periocular/intraocular injection of any corticosteroid solution - 4 weeks (see exception 5b) * Corticosteroid depot/implant in the study eye - 2 months * Topical ocular corticosteroid - 7 days * Topical ocular NSAID - 7 days * Intraoperatively used intraocular steroid (i.e. intravitreal triamcinolone, that is used to transiently highlight the vitreous and removed during vitrectomy) is permissible in study eye. * Intraoperatively or perioperatively used systemic steroid for the purpose of general anesthesia (as administered by the treating anesthesiologist) is permissible. * Patients with systemic illness involving abnormalities of the hypothalamic-pituitary-adrenal axis; patients with primary adrenocortical insufficiency or adrenocortical hyperfunction. * Patients with known hypersensitivity to Dexamethasone. * Patients with uncontrolled glaucoma. * Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator.